@article{RoseDammGreineretal.2014,
  author    = {Rose, Markus A. and Damm, Oliver and Greiner, Wolfgang and Knuf, Markus and Wutzler, Peter and Liese, Johannes G. and Kr{\"u}ger, Hagen and Wahn, Ulrich and Schaberg, Tom and Schwehm, Markus and Kochmann, Thomas F. and Eichner, Martin},
  title     = {The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study},
  series = {BMC Infectious Diseases},
  volume    = {14},
  journal   = {BMC Infectious Diseases},
  number    = {40},
  issn      = {1471-2334},
  doi       = {10.1186/1471-2334-14-40},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117563},
  year      = {2014},
  abstract  = {Background: Routine annual influenza vaccination is primarily recommended for all persons aged 60 and above and for people with underlying chronic conditions in Germany. Other countries have already adopted additional childhood influenza immunisation programmes. The objective of this study is to determine the potential epidemiological impact of implementing paediatric influenza vaccination using intranasally administered live-attenuated influenza vaccine (LAIV) in Germany. Methods: A deterministic age-structured model is used to simulate the population-level impact of different vaccination strategies on the transmission dynamics of seasonal influenza in Germany. In our base-case analysis, we estimate the effects of adding a LAIV-based immunisation programme targeting children 2 to 17 years of age to the existing influenza vaccination policy. The data used in the model is based on published evidence complemented by expert opinion. Results: In our model, additional vaccination of children 2 to 17 years of age with LAIV leads to the prevention of 23.9 million influenza infections and nearly 16 million symptomatic influenza cases within 10 years. This reduction in burden of disease is not restricted to children. About one third of all adult cases can indirectly be prevented by LAIV immunisation of children. Conclusions: Our results demonstrate that vaccinating children 2-17 years of age is likely associated with a significant reduction in the burden of paediatric influenza. Furthermore, annual routine childhood vaccination against seasonal influenza is expected to decrease the incidence of influenza among adults and older people due to indirect effects of herd protection. In summary, our model provides data supporting the introduction of a paediatric influenza immunisation programme in Germany.},
  language  = {en}
}
@article{SauerbreiLangenhanBrandstaedtetal.2014,
  author    = {Sauerbrei, A. and Langenhan, T. and Brandst{\"a}dt, A. and Schmidt-Ott, R. and Krumbholz, A. and Girschick, H. and Huppertz, H. and Kaiser, P. and Liese, J. and Streng, A. and Niehues, T. and Peters, J. and Sauerbrey, A. and Schroten, H. and Tenenbaum, T. and Wirth, S. and Wutzler, P.},
  title     = {Prevalence of antibodies against influenza A and B viruses in children in Germany, 2008 to 2010},
  series = {Eurosurveillance},
  volume    = {19},
  journal   = {Eurosurveillance},
  number    = {5},
  issn      = {1560-7917},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117347},
  pages     = {20687},
  year      = {2014},
  abstract  = {The prevalence of influenza A and B virus-specific IgG was determined in sera taken between 2008 and 2010 from 1,665 children aged 0-17 years and 400 blood donors in Germany. ELISA on the basis of whole virus antigens was applied. Nearly all children aged nine years and older had antibodies against influenza A. In contrast, 40\% of children aged 0-4 years did not have any influenza A virus-specific IgG antibodies. Eighty-six percent of 0-6 year-olds, 47\% of 7-12 year-olds and 20\% of 13-17 year-olds were serologically naive to influenza B viruses. By the age of 18 years, influenza B seroprevalence reached approximately 90\%. There were obvious regional differences in the seroprevalence of influenza B in Germany. In conclusion, seroprevalences of influenza A and influenza B increase gradually during childhood. The majority of children older than eight years have basal immunity to influenza A, while comparable immunity against influenza B is only acquired at the age of 18 years. Children aged 0-6 years, showing an overall seroprevalence of 67\% for influenza A and of 14\% for influenza B, are especially at risk for primary infections during influenza B seasons.},
  language  = {en}
}
@article{KaramustafalıoğluReifAtmacaetal.2014,
  author    = {Karamustafal{\i}oğlu, Oğuz and Reif, Andreas and Atmaca, Murad and Gonzalez, Domingo and Moreno-Manzanaro, Miriam and Gonzalez, Miguel Angel and Medina, Esteban and Bellomo, Antonello},
  title     = {Hospital stay in patients admitted for acute bipolar manic episodes prescribed quetiapine immediate or extended release: a retrospective non-interventional cohort study (HOME)},
  series = {BMC Psychiatry},
  volume    = {14},
  journal   = {BMC Psychiatry},
  number    = {246},
  doi       = {10.1186/s12888-014-0246-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-115547},
  year      = {2014},
  abstract  = {Background: Bipolar manic episodes often require hospital admission to ensure patient safety. The antipsychotic quetiapine is a common treatment for bipolar mania and is available in immediate release (IR) and extended release (XR) formulations; however, outcomes in patients receiving these different formulations have not been directly compared in an acute hospital setting. Methods: We conducted a multinational, observational, retrospective cohort study to describe and compare hospital stay in patients admitted for an acute bipolar manic episode treated with quetiapine IR or XR from 1 October 2009-1 October 2010. The primary outcome measure was comparison of length of stay (LOS) using zero-truncated negative binomial regression. Results: In total, 1230 patients were included (659 in the IR cohort; 571 in the XR cohort). The median LOS (interquartile range) was 18.0 days (12.0, 28.0) in the IR cohort and 20.0 days (12.0, 34.0) in the XR cohort, respectively. LOS was not significantly associated with quetiapine formulation irrespective of whether or not clinical characteristics were taken into account (p = 0.820 and p = 0.386, respectively). Overall, 84.2\% and 84.4\% of patients in the IR and XR cohorts, respectively, had not previously used quetiapine; of these patients, 78.7\% and 68.9\% received one total daily dose, and 14.4\% and 23.9\% received dose titration. Over half of patients received antipsychotic monotherapy (53.1\% and 58.3\% in the IR and XR cohorts, respectively) and most received a daily quetiapine dose >= 400 mg (64.9\% and 71.8\%, respectively, for quetiapine monotherapy and 59.9\% and 80.3\%, respectively, for combination treatment). As a secondary outcome, multivariate analysis was used to identify other factors that affect LOS. Factors associated with a longer hospital stay included public funding versus private, maximum number of new medications administered, did not receive lithium and did not receive anxiolytics, sedatives/hypnotics (all p < 0.0001). Factors associated with a shorter hospital stay included presence of drug/alcohol abuse, living accompanied and having a psychiatric medical history (all p < 0.05). Conclusions: LOS was not found to be associated with quetiapine formulation. However, most patients received only one total daily dose of quetiapine without dose titration, which was unexpected and contrary to current recommendations.},
  language  = {en}
}